Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Cellmid Limited

Investor presentation - Cellmid Limited

ASX:CDY

Cellmid Limited

Health

Cellmid Limited (CDY) is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets in novative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. They operate through two business segment Midikine and Consumer health.

Read more

Market Cap

$13.36m

Price at Close

$0.105

4w avg. Volume

101.46k

4w avg. Turnover

$11.06k

Announcements
announcementt+2 movementdate
  • Cellmid Receives First Order From Chinese Distributor

    Progress Report · Market sensitive

  • -

    24 Jan 2021

-

24 Jan 2021
  • Appendix 2A

    Issued Capital

  • +4.76%

    15 Jan 2021

+4.76%

15 Jan 2021
  • Final Director's Interest Notice - King

    Shareholder Details

  • -8.70%

    04 Jan 2021

-8.70%

04 Jan 2021
  • Change of Director's Interest Notice - Gordon

    Shareholder Details

  • -4.35%

    30 Dec 2020

-4.35%

30 Dec 2020
  • Change of Director's Interest Notice - Halasz

    Shareholder Details

  • -4.35%

    30 Dec 2020

-4.35%

30 Dec 2020
  • Change of Director's Interest Notice - King

    Shareholder Details

  • -4.35%

    30 Dec 2020

-4.35%

30 Dec 2020
  • Confirming Changes to the Cellmid Board

    Company Administration

  • 0.00%

    23 Dec 2020

0.00%

23 Dec 2020
  • Newsletter

    Progress Report

  • 0.00%

    23 Dec 2020

0.00%

23 Dec 2020
  • Change of Director's Interest Notice - Eck

    Shareholder Details

  • -4.55%

    15 Dec 2020

-4.55%

15 Dec 2020
  • Appendix 2A

    Issued Capital

  • -4.55%

    15 Dec 2020

-4.55%

15 Dec 2020
Market Data

Current Price

$0.105

52WK HIGH

$0.49

52WK LOW

$0.083

1YR RETURN

-54.35%

1YR RETURN VS. SECTOR

-93.03%

90 DAY RETURN

0.00%

ASX RANK

1,714

/2,048

SECTOR RANK

158

/168

SHARES OUTSTANDING

127.21m
ASX:CDY

Cellmid Limited

Health

Cellmid Limited (CDY) is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets in novative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. They operate through two business segment Midikine and Consumer health.

Read more

Market Cap

$13.36m

Price at Close

$0.105

4w avg. Volume

101.46k

4w avg. Turnover

$11.06k

ASX:CDY is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.